AstraZeneca PLC (AZN) Shares Outstanding: 1.55
Is AstraZeneca PLC’s shares outstanding high or low?
AstraZeneca PLC's shares outstanding of 1.55 is in line with its 5-year average of 1.49, near the high end of its 5-year range (1.31–1.56).
In line with its 12-month average of 1.55.
AZN Shares Outstanding Chart
AZN Average Shares Outstanding Chart
AZN Current vs Average Shares Outstanding Chart
AZN Shares Outstanding Metrics
SHARES OUTSTANDING
1.55
SHARES OUTSTANDING AVG TTM
1.55
SHARES OUTSTANDING AVG 3Y
1.55
SHARES OUTSTANDING AVG 5Y
1.49
SHARES OUTSTANDING AVG 10Y
1.39
SHARES OUTSTANDING AVG 15Y
1.37
SHARES OUTSTANDING AVG 20Y
1.40
CURRENT VS TTM AVG
+0.00%
CURRENT VS 3Y AVG
-0.16%
CURRENT VS 5Y AVG
+4.03%
CURRENT VS 10Y AVG
+11.42%
CURRENT VS 15Y AVG
+13.36%
CURRENT VS 20Y AVG
+10.51%
Share Structure
Shares Outstanding
1.55B
Float Shares
N/A
Stock Price
$182.28
Market Cap
$282.7B
Annual Shares Outstanding History
| Year | Weighted Average Shares | YoY Change |
|---|---|---|
| 2025 | 1.55B | +0.00% |
| 2024 | 1.55B | -0.77% |
| 2023 | 1.56B | +0.90% |
| 2022 | 1.55B | +9.17% |
| 2021 | 1.42B | +8.08% |
| 2020 | 1.31B | +0.85% |
| 2019 | 1.30B | +2.68% |
| 2018 | 1.27B | +0.08% |
| 2017 | 1.27B | +0.08% |
| 2016 | 1.26B | +0.08% |
| 2015 | 1.26B | +0.16% |
| 2014 | 1.26B | +0.80% |
| 2013 | 1.25B | -0.71% |
| 2012 | 1.26B | -7.35% |
| 2011 | 1.36B | -5.35% |
| 2010 | 1.44B | -0.69% |
| 2009 | 1.45B | -0.34% |
| 2008 | 1.45B | -2.81% |
| 2007 | 1.50B | -4.41% |
| 2006 | 1.56B | -3.28% |
| 2005 | 1.62B | -3.35% |
| 2004 | 1.67B | -2.11% |
| 2003 | 1.71B | -1.38% |
| 2002 | 1.73B | -1.42% |
| 2001 | 1.76B | -0.57% |
| 2000 | 1.77B | -0.45% |
| 1999 | 1.78B | +90.23% |
| 1998 | 933.60M | -1.52% |
| 1997 | 948.00M | +0.11% |
| 1996 | 947.00M | - |
Relationship: Market Cap = Shares Outstanding × Stock Price
Key concepts:
- Float shares: Shares available for public trading
- Dilution: When new shares are issued, existing shareholders own less
- Buybacks: Reduce share count, increasing EPS and ownership stake
- Stock splits: Increase share count but don't change market cap
AstraZeneca PLC Shares Outstanding Formula & Definition
Shares Outstanding represents the total number of shares issued by a company that are held by all shareholders. Changes in share count affect EPS and ownership dilution.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
AstraZeneca PLC Shares Outstanding FAQ
- What is the shares outstanding for AstraZeneca PLC (AZN)?
- The shares outstanding for AZN stock is 1.55.
- Is AstraZeneca PLC's shares outstanding high or low?
- AstraZeneca PLC's shares outstanding of 1.55 is in line with its 5-year average of 1.49, near the high end of its 5-year range (1.31–1.56).
- What is the TTM average shares outstanding for AstraZeneca PLC (AZN)?
- The TTM average shares outstanding for AZN stock is 1.55.
- What is the 3Y average shares outstanding for AstraZeneca PLC (AZN)?
- The 3Y average shares outstanding for AZN stock is 1.55.
- What is the 5Y average shares outstanding for AstraZeneca PLC (AZN)?
- The 5Y average shares outstanding for AZN stock is 1.49.
- What is the 10Y average shares outstanding for AstraZeneca PLC (AZN)?
- The 10Y average shares outstanding for AZN stock is 1.39.
- What is the 15Y average shares outstanding for AstraZeneca PLC (AZN)?
- The 15Y average shares outstanding for AZN stock is 1.37.
- What is the 20Y average shares outstanding for AstraZeneca PLC (AZN)?
- The 20Y average shares outstanding for AZN stock is 1.40.
AstraZeneca PLC Shares Outstanding History
| DATE | SHARES OUTSTANDING |
|---|---|
| 2025-12-31 | 1.55 |
| 2024-12-31 | 1.55 |
| 2023-12-31 | 1.56 |
| 2022-12-31 | 1.55 |
| 2021-12-31 | 1.42 |
| 2020-12-31 | 1.31 |
| 2019-12-31 | 1.30 |
| 2018-12-31 | 1.27 |
| 2017-12-31 | 1.27 |
| 2016-12-31 | 1.26 |
| 2015-12-31 | 1.26 |
| 2014-12-31 | 1.26 |
| 2013-12-31 | 1.25 |
| 2012-12-31 | 1.26 |
| 2011-12-31 | 1.36 |
| 2010-12-31 | 1.44 |
| 2009-12-31 | 1.45 |
| 2008-12-31 | 1.45 |
| 2007-12-31 | 1.50 |
| 2006-12-31 | 1.56 |
| 2005-12-31 | 1.62 |
| 2004-12-31 | 1.67 |
| 2003-12-31 | 1.71 |
| 2002-12-31 | 1.73 |
| 2001-12-31 | 1.76 |
| 2000-12-31 | 1.77 |
| 1999-12-31 | 1.78 |
| 1998-12-31 | 0.93 |
| 1997-12-31 | 0.95 |
| 1996-12-31 | 0.95 |
Related Metrics
About AstraZeneca PLC
AstraZeneca PLC operates as a global biopharmaceutical leader, dedicated to the entire process of bringing prescription medicines to market, from their initial discovery and development through manufacturing and commercialization. The company's extensive portfolio of treatments, including prominent examples like Tagrisso, Farxiga, and Symbicort, addresses critical areas such as cardiovascular, renal, metabolic, and oncological conditions. Furthermore, it provides essential solutions for COVID-19 and various rare diseases, with products like Vaxzevria and Soliris. AstraZeneca engages with primary and specialty care physicians worldwide, facilitating distribution through a robust network of representatives and local offices across the United Kingdom, continental Europe, the Americas, Asia, Africa, and Australasia. The firm actively drives innovation through strategic collaborations, partnering with entities such as Neurimmune AG for the development and commercialization of NI006, BenevolentAI for systemic lupus erythematosus drug discovery, Lunit for AI-powered digital pathology risk assessment in NSCLC, and Absci Corporation for AI-driven oncology target identification. Founded in 1992, the company was initially known as Zeneca Group PLC, subsequently rebranding to AstraZeneca PLC in April 1999, and maintains its headquarters in Cambridge, United Kingdom.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- CEO
- Pascal Claude Roland Soriot